- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Patent holdings for IPC class A61P 19/02
Total number of patents in this class: 6722
10-year publication summary
|
274
|
268
|
252
|
380
|
492
|
518
|
583
|
586
|
531
|
149
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 11238 |
81 |
| Takeda Pharmaceutical Company Limited | 2961 |
76 |
| Bristol-myers Squibb Company | 5080 |
72 |
| Daiichi Sankyo Company, Limited | 1829 |
55 |
| F. Hoffmann-La Roche AG | 7958 |
54 |
| Merck Patent GmbH | 5909 |
50 |
| AstraZeneca AB | 3042 |
44 |
| Jiangsu Hengrui Medicine Co., Ltd. | 780 |
42 |
| The Regents of the University of California | 18943 |
39 |
| Janssen Pharmaceutica N.V. | 3839 |
38 |
| Galapagos NV | 304 |
35 |
| Boehringer Ingelheim International GmbH | 4629 |
33 |
| Regeneron Pharmaceuticals, Inc. | 3650 |
33 |
| Shionogi & Co., Ltd. | 914 |
33 |
| Ono Pharmaceutical Co., Ltd. | 454 |
32 |
| Mitsubishi Tanabe Pharma Corporation | 579 |
31 |
| Amgen Inc. | 3779 |
30 |
| Eli Lilly and Company | 3645 |
30 |
| Osaka University | 3143 |
29 |
| Astellas Pharma Inc. | 1145 |
28 |
| Other owners | 5857 |